Nosál R, Jancinová V, Petríková M
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava.
Biochem Pharmacol. 1994 Jun 15;47(12):2207-11. doi: 10.1016/0006-2952(94)90257-7.
A significant concentration-dependent difference was found between beta-adrenoceptor blocking drugs in their ability to inhibit A23187-induced isolated platelet aggregation. In the absence of extracellular calcium ions the following rank order of potency to inhibit calcium ionophore stimulated platelet aggregation was shown: propranolol > bevantolol > alprenolol > metipranolol > oxprenolol > atenolol > pindolol > metoprolol approximately sotalol approximately practolol. The interruption of induced aggregation, as well as inhibition of aggregation, in the absence of extracellular calcium ions indicated interference of inhibitory beta-adrenoceptor blocking drugs with intramembrane or intraplatelet calcium pools activated with A23187. This suggestion was supported by the reversal of the inhibitory effect of beta-adrenoceptor blocking drugs in the presence of extracellular calcium ions. The effect was dose dependent and occurred within 30 sec after calcium administration. The results indicated that inhibitory beta-adrenoceptor blocking drugs, possessing a cationic amphiphilic structure, suppressed calcium mobilization in A23187-stimulated platelets, most probably after entering platelets. This explains why lipophilic drugs are more effective than hydrophilic ones in calcium ionophore A23187-stimulated platelets.
在β-肾上腺素受体阻断药物抑制A23187诱导的离体血小板聚集的能力方面,发现了显著的浓度依赖性差异。在无细胞外钙离子的情况下,显示出抑制钙离子载体刺激的血小板聚集的效力顺序如下:普萘洛尔>贝凡洛尔>阿普洛尔>美替洛尔>氧烯洛尔>阿替洛尔>吲哚洛尔>美托洛尔≈索他洛尔≈普拉洛尔。在无细胞外钙离子的情况下,诱导聚集的中断以及聚集的抑制表明,抑制性β-肾上腺素受体阻断药物干扰了由A23187激活的膜内或血小板内钙库。细胞外钙离子存在时β-肾上腺素受体阻断药物抑制作用的逆转支持了这一观点。该效应呈剂量依赖性,在给予钙离子后30秒内出现。结果表明,具有阳离子两亲结构的抑制性β-肾上腺素受体阻断药物,很可能在进入血小板后,抑制了A23187刺激的血小板中的钙动员。这解释了为什么在钙离子载体A23187刺激的血小板中,脂溶性药物比亲水性药物更有效。